Cargando…

Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity

Botulinum toxin (BT) is a potent presynaptic neuromuscular blocking agent which induces selective, reversible muscle weakness for months when injected intramuscularly. During recent years BT has revolutionized the treatment of previously intractable symptoms of detrusor overactivity. Based on a syst...

Descripción completa

Detalles Bibliográficos
Autores principales: Rohrsted, Malene, Nordsten, Cecilie Bagi, Bagi, Per
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614280/
https://www.ncbi.nlm.nih.gov/pubmed/23573462
http://dx.doi.org/10.5812/numonthly.1864
_version_ 1782264819772030976
author Rohrsted, Malene
Nordsten, Cecilie Bagi
Bagi, Per
author_facet Rohrsted, Malene
Nordsten, Cecilie Bagi
Bagi, Per
author_sort Rohrsted, Malene
collection PubMed
description Botulinum toxin (BT) is a potent presynaptic neuromuscular blocking agent which induces selective, reversible muscle weakness for months when injected intramuscularly. During recent years BT has revolutionized the treatment of previously intractable symptoms of detrusor overactivity. Based on a systematic search of the PubMed database, a review of the current literature on the use of onabotulinum toxin A (Botox®) in the treatment of neurogenic detrusor overactivity is presented. Onabotulinum toxin A proved to be highly effective in the majority of studies, even though a wide range of injection techniques and dosages were described. The onset of the effect usually appeared before 2 weeks, and reached a peak within 2-6 weeks, with the clinical effect being maintained for approximately 6-8 months, or even longer. Depending on the dose, a number of patients developed high residual volume and clean intermittent self/helper catheterization (CIC) may become necessary. Only a few side effects were described, and intravesical onabotulinum toxin A injection seems to be well tolerated. However, details on injection technique, dose interval between injections, etc. are still under debate and only a few randomized, placebo controlled studies have been published.
format Online
Article
Text
id pubmed-3614280
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Kowsar
record_format MEDLINE/PubMed
spelling pubmed-36142802013-04-09 Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity Rohrsted, Malene Nordsten, Cecilie Bagi Bagi, Per Nephrourol Mon Review Article Botulinum toxin (BT) is a potent presynaptic neuromuscular blocking agent which induces selective, reversible muscle weakness for months when injected intramuscularly. During recent years BT has revolutionized the treatment of previously intractable symptoms of detrusor overactivity. Based on a systematic search of the PubMed database, a review of the current literature on the use of onabotulinum toxin A (Botox®) in the treatment of neurogenic detrusor overactivity is presented. Onabotulinum toxin A proved to be highly effective in the majority of studies, even though a wide range of injection techniques and dosages were described. The onset of the effect usually appeared before 2 weeks, and reached a peak within 2-6 weeks, with the clinical effect being maintained for approximately 6-8 months, or even longer. Depending on the dose, a number of patients developed high residual volume and clean intermittent self/helper catheterization (CIC) may become necessary. Only a few side effects were described, and intravesical onabotulinum toxin A injection seems to be well tolerated. However, details on injection technique, dose interval between injections, etc. are still under debate and only a few randomized, placebo controlled studies have been published. Kowsar 2012-03-01 2012 /pmc/articles/PMC3614280/ /pubmed/23573462 http://dx.doi.org/10.5812/numonthly.1864 Text en Copyright © 2012 Kowsar M. P. Co. All rights reserved. http://creativecommons.org/licenses/by/3/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Rohrsted, Malene
Nordsten, Cecilie Bagi
Bagi, Per
Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity
title Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity
title_full Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity
title_fullStr Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity
title_full_unstemmed Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity
title_short Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity
title_sort onabotulinum toxin a (botox®) in the treatment of neurogenic bladder overactivity
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614280/
https://www.ncbi.nlm.nih.gov/pubmed/23573462
http://dx.doi.org/10.5812/numonthly.1864
work_keys_str_mv AT rohrstedmalene onabotulinumtoxinabotoxinthetreatmentofneurogenicbladderoveractivity
AT nordstenceciliebagi onabotulinumtoxinabotoxinthetreatmentofneurogenicbladderoveractivity
AT bagiper onabotulinumtoxinabotoxinthetreatmentofneurogenicbladderoveractivity